ArticleNature communications2018
The intralumenal fragment pathway mediates ESCRT-independent surface transporter down-regulation.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Lysosomal quality control Review.Autophagy · 2025Review
- LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer.Molecular cancer · 2024Article
- Embryonic signals mediate extracellular vesicle biogenesis and trafficking at the embryo-maternal interface.Cell communication and signaling : CCS · 2023Article
- A two-tiered system for selective receptor and transporter protein degradation.PLoS genetics · 2022Article
- Engineering stem cells to produce exosomes with enhanced bone regeneration effects: an alternative strategy for gene therapy.Journal of nanobiotechnology · 2022Article
- The endosomal sorting complex required for transport repairs the membrane to delay cell death.Frontiers in oncology · 2022Review
- Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis.Frontiers in immunology · 2022Review
- Location, location, location: subcellular protein partitioning in proteostasis and aging.Biophysical reviews · 2021Review
- Autophagy in major human diseases.The EMBO journal · 2021Review
- How the vacuole ESCRTs its own proteins to their final destination.The Journal of cell biology · 2021Article
- ESCRT, not intralumenal fragments, sorts ubiquitinated vacuole membrane proteins for degradation.The Journal of cell biology · 2021Article
- Lysosome Depletion-Triggered Autophagy Impairment in Progressive Kidney Injury.Kidney diseases (Basel, Switzerland) · 2021Review
- Cellular signaling cross-talk between different cardiac cell populations: an insight into the role of exosomes in the heart diseases and therapy.American journal of physiology. Heart and circulatory physiology · 2021Review
- The Role of Non-Immune Cell-Derived Extracellular Vesicles in Allergy.Frontiers in immunology · 2021Review
- Through the back door: Unconventional protein secretion.Cell surface (Amsterdam, Netherlands) · 2020Review
- ESCRT machinery plays a role in microautophagy in yeast.BMC molecular and cell biology · 2020Article
- Focus on the morphogenesis, fate and the role in tumor progression of multivesicular bodies.Cell communication and signaling : CCS · 2020Review
- Article
- Life in the lumen: The multivesicular endosome.Traffic (Copenhagen, Denmark) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surface receptor and transporter protein down-regulation is assumed to be exclusively mediated by the canonical multivesicular body (MVB) pathway and ESCRTs (Endosomal Sorting Complexes Required for Transport). However, few surface proteins are known to require ESCRTs for down-regulation, and reports of ESCRT-independent degradation are emerging, suggesting that alternative pathways exist. Here, using Saccharomyces cerevisiae as a model, we show that the hexose transporter Hxt3 does not require ESCRTs for down-regulation conferring resistance to 2-deoxyglucose. This is consistent with GFP-tagged Hxt3 bypassing ESCRT-mediated entry into intralumenal vesicles at endosomes. Instead, Hxt3-GFP accumulates on vacuolar lysosome membranes and is sorted into an area that, upon fusion, is internalized as an intralumenal fragment (ILF) and degraded. Moreover, heat stress or cycloheximide trigger degradation of Hxt3-GFP and other surface transporter proteins (Itr1, Aqr1) by this ESCRT-independent process. How this ILF pathway compares to the MVB pathway and potentially contributes to physiology is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.